Searching On:

Drug:

GSK1120212

View:
Expand Collapse GSK1120212  - General Description Mekinist (MEH-kih-nist)
A drug used alone or with dabrafenib to treat melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients with a mutated (changed) form of a cell protein called BRAF. It is also being studied in the treatment of other types of cancer. Mekinist blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor and a type of targeted therapy. Also called trametinib.
Chemical Name
N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide
Drug Code Name
GSK1120212
JTP-74057
Trametinib
US Brand Names
Mekinist
Mekinist (MEH-kih-nist)
A drug used alone or with dabrafenib to treat melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients with a mutated (changed) form of a cell protein called BRAF. It is also being studied in the treatment of other types of cancer. Mekinist blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor and a type of targeted therapy. Also called trametinib.
Chemical Name
N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide
Drug Code Name
GSK1120212
JTP-74057
Trametinib
US Brand Names
Mekinist

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Drug
Trial Status: Showing all 4 results Per Page:
Protocol # Title Location Status Match
NCT01989585 Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery MGH Open D
NCT02079740 Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors MGH Open D
NCT02110355 A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma MGH Open D
NCT02296112 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations MGH Open D
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 4 results Per Page:

Share with your Physican

Print information for your Physician.

Print information